- Home
- AGIO vs SANA Comparison
AGIO vs SANA Comparison
Compare AGIO & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | SANA |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGIO | SANA |
|---|---|---|
| Price | $27.39 | $5.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $32.13 | $7.83 |
| AVG Volume (30 Days) | 2.7M | ★ 5.2M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,791,000.00 | N/A |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $139.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.26 | N/A |
| 52 Week Low | $22.24 | $1.26 |
| 52 Week High | $46.00 | $7.30 |
Technical Indicators
Market Signals| Indicator | AGIO | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 61.08 |
| Support Level | $26.80 | $4.25 |
| Resistance Level | $28.61 | $5.43 |
| Average True Range (ATR) | 1.19 | 0.50 |
| MACD | 0.25 | 0.14 |
| Stochastic Oscillator | 56.00 | 84.27 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.